Assertio Holdings, Inc.ASRTEarnings & Financial Report
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...
Revenue
$32.4M
Gross Profit
N/A
Operating Profit
$-4.3M
Net Profit
$-4.5M
Gross Margin
N/A
Operating Margin
-13.4%
Net Margin
-13.9%
YoY Growth
-23.6%
EPS
$-0.05
Assertio Holdings, Inc. Q1 FY2024 Financial Summary
Assertio Holdings, Inc. reported revenue of $32.4M (down 23.6% YoY) for Q1 FY2024, with a net profit of $-4.5M (down 29.4% YoY) (-13.9% margin).
Key Financial Metrics
| Total Revenue | $32.4M |
|---|---|
| Net Profit | $-4.5M |
| Gross Margin | N/A |
| Operating Margin | -13.4% |
| Report Period | Q1 FY2024 |
Assertio Holdings, Inc. Annual Revenue by Year
Assertio Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $118.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $118.7M |
| 2024 | $125.0M |
| 2023 | $152.1M |
| 2022 | $156.2M |
Assertio Holdings, Inc. Quarterly Revenue & Net Profit History
Assertio Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.5M | -57.9% | N/A | N/A |
| Q3 FY2025 | $49.5M | +69.4% | $11.4M | 23.1% |
| Q2 FY2025 | $29.2M | -6.1% | $-16.4M | -56.0% |
| Q1 FY2025 | $26.5M | -18.4% | $-13.5M | -51.1% |
| Q4 FY2024 | $32.2M | -2.4% | N/A | N/A |
| Q3 FY2024 | $29.2M | -18.0% | $-2.9M | -10.0% |
| Q2 FY2024 | $31.1M | -24.1% | $-3.7M | -11.8% |
| Q1 FY2024 | $32.4M | -23.6% | $-4.5M | -13.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.4M | $31.1M | $29.2M | $32.2M | $26.5M | $29.2M | $49.5M | $13.5M |
| YoY Growth | -23.6% | -24.1% | -18.0% | -2.4% | -18.4% | -6.1% | 69.4% | -57.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $282.0M | $279.4M | $276.0M | $284.7M | $286.4M | $273.8M | $319.8M | $267.0M |
| Liabilities | $147.5M | $147.3M | $145.5M | $163.7M | $177.9M | $180.5M | $214.0M | $173.0M |
| Equity | $134.5M | $132.2M | $130.5M | $121.1M | $108.5M | $93.3M | $105.8M | $94.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.5M | $7.4M | $-35000 | $11.5M | $-12.5M | $19.1M | $-4.8M | $-30.0M |